Advanced searches left 3/3

Carboplatin Paclitaxel Phase - Crossref

Summarized by Plex Scholar
Last Updated: 03 January 2023

* If you want to update the article please login/register

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Abstract Abstract: Patients with metastatic PD-L1 positive triple negative breast cancer with chemotherapy have improved progression-free and overall survival. This trial compared neoplatin and paclitaxel with or without atezolizumab in patients with clinical stage II-III TNBC. In the mITT population, chemotherapy and atezolizumab could raise the pCR rate and tumor infiltrating lymphocyte percentage, which is higher than chemotherapy alone. During the follow-up period, one patient in Arm B died of recurrent disease. Patients with pCR had higher median TIL percentages than those with non-pCR. Although subgroup analyses were limited due to the small sample size, PD-L1-positive patients treated with chemotherapy and atezolizumab had a 75% pCR rate, according to the authors. The addition of atezolizumab to neoadjuvant carboplatin and paclitaxel resulted in a clinically significant and clinically relevant rise in patients with clinical stages II and III TNBC.

Source link: https://doi.org/10.1038/s41523-022-00500-3


Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer

Abstract Background In this phase II clinical trial, we determined the safety of the nonanthracycline combination of carboplatin and nab-paclitaxel in early stage triple-negative breast cancer. Patients and Methods Patients with newly diagnosed stage II–U2013III TNBC were given neoadjuvant carboplatin every 28 days for four cycles plus nab-paclitaxel weekly for 16 weeks, with neoadjuvant carboplatin every 28 days for four cycles. At least one dose delay was present in the patient, and 50 percent required dose reduction. 31 of 67 patients had pCR, ten of 67 had RCB II, 19 of 67 had RCB II, 5 of 67 had RCB II, 5 of 67 had RCB III, and 1 of 67 had no surgery; the remainder of 67 patients had no surgery. According to RCB II/III, with odds ratios 4. 80 to RCB II/III, an immune-hot GSIS and DNA repair defect were associated with higher pCR with higher pCR with odds ratios of 4. 62 and 4. 76, respectively, and with RCB 0/I versus RCB II/III. Conclusion The combination of carboplatin and nab-paclitaxel for early stage high-risk TNBC showed manageable toxicity while also increasing anti-tumor activity, according to the author. NCT01525966 Effects of Practice Platinum is a key neoadjuvant chemotherapy agent for the treatment of early stage triple-negative breast cancer. In univariate and multivariate studies adjusting for age, race, tumor stage, and grade, u201cimmune-hot u201d GeparSixto immune signature, and residual cancer burden class 0/1 were correlated with increased pathological complete response and residual cancer burden class 0/1. Patients with early stage TNBC have been recommended for de-escalating neoadjuvant chemotherapy for patients with high pCR.

Source link: https://doi.org/10.1002/onco.13574


NEOADJUVANT CARBOPLATIN AND PACLITAXEL FOLLOWED BY RADICAL HYSTERECTOMY AND ADJUVANT CISPLATIN CHEMORADIATION: PHASE II STUDY EVALUATION OF MULTIMODALITY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER

Materials and Method: IB2-IIIB's patented type III hysterectomy, adjuvant radiation therapy, and 6-weekly doses of cisplatin at 35 mg/m2 were given to 40 patients staged as IB2-IIIB over a period of three 20-day courses of carboplatin and paclitaxel. In 16% and 19% of the patients who underwent surgery; positive surgical boundaries were established in 11% of the patients; positive pelvic lymph nodes were present in 19% of the patients; and positive pelvic lymph nodes were found in 19% of the patients. A median of 4 cisplatin treatments was given together with a mean dose of 49. 2 Gy over the course of 42. 7 days. Both Neutropenia grades 3 and 4 were well tolerated with neoadjuvant therapy in 11% and 2% of the courses, respectively. Conclusion: The combination of neoadjuvant chemotherapy, radical hysterectomy, and adjuvant radiotherapy in place of cisplatin is a highly safe and tolerable treatment for locally advanced cervical cancer.

Source link: https://doi.org/10.5455/ijmrcr.172-1667476767


Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Abstract Background The nonsquamous non-u2013small cell lung cancer treatment has undergone a paradigm shift to platinum combination therapy with immune checkpoint inhibitors, as well as immune checkpoint inhibitors. However, phase III trials of cytotoxic chemotherapy and ICIs of combination of cytotoxic chemotherapy and ICIs have included only patients with preserved organ function, not those with renal impairment. Discussion If the research shows the effectiveness and safety of carboplatin/nab-paclitaxel/atezolizumab, it may be a treatment option for non-squamous NSCLC patients with impaired renal function.

Source link: https://doi.org/10.1186/s12885-022-10056-x


POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

History Squamous carcinoma of the anal canal in a localized or recurrent setting is a human papillomavirus-driven disease with poor prognosis. Retrospectib based chemotherapy exhibited strong clinical growth and an anticipated safety profile in patients with advanced SCAC who have advanced SCAC who started on platinum-based chemotherapy in POD1UM-202. POD1UM-303/InterAct 2, a phase III, double-blind, multiregional study, investigates the addition of retifanlimab to the care carboplatinab in patients with acute or metastatic SCACs who have not previously treated with systemic chemotherapy, based on these promising findings. Patients can be induction cycles of carboplatin and paclitaxel every 28 days in SOC. In the absence of unacceptable toxicity, disease progression, withdrawal of consent, loss to follow-up, or premature discontinuation, retinlimab 500 mg or placebo will be administered intravenously in a blinded fashion on day 1 of every 28-day cycle for up to 13 cycles.

Source link: https://doi.org/10.3389/fonc.2022.935383

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions